Controversial penalty sparks 2-0 Ipswich win at Norwich Bottom-side Wednesday draw 0-0 at leaders Coventry Ipswich gave their hopes of automatic promotion a massive boost by recording a hard-fought 2-0 win over Norwich at Carrow Road, while Coventry must wait for another day after being held 0-0 at home by Sheffield Wednesday . Ipswich moved into the top two, with at least a game in hand on their ...
Controversial penalty sparks 2-0 Ipswich win at Norwich Bottom-side Wednesday draw 0-0 at leaders Coventry Ipswich gave their hopes of automatic promotion a massive boost by recording a hard-fought 2-0 win over Norwich at Carrow Road, while Coventry must wait for another day after being held 0-0 at home by Sheffield Wednesday . Ipswich moved into the top two, with at least a game in hand on their nearest rivals, as first-half goals from Jaden Philogene, with a harsh penalty, and George Hirst completed a long overdue double over their East Anglian rivals. This story will be updated Continue reading...
Luis Alvarez/DigitalVision via Getty Images AVIV Overview The Avantis International Large Cap Value ETF ( AVIV ) is an actively managed exchange-traded fund with a NAV around $1.2Bn that invests in large-capitalization equity securities outside the U.S. AVIV is a direct equity fund—it holds individual stocks, not other ETFs. The fund's benchmark target is the MSCI World ex USA Value Index, which c...
Luis Alvarez/DigitalVision via Getty Images AVIV Overview The Avantis International Large Cap Value ETF ( AVIV ) is an actively managed exchange-traded fund with a NAV around $1.2Bn that invests in large-capitalization equity securities outside the U.S. AVIV is a direct equity fund—it holds individual stocks, not other ETFs. The fund's benchmark target is the MSCI World ex USA Value Index, which covers large- and mid-cap value-style companies across 22 developed markets outside the U.S. The value investment style characteristics for index construction are with three variables: book value to price, 12-month forward earnings to price, and dividend yield. While the current geopolitical shock has dragged the fund off its 52-week high of $80.80, the fund is trading in line with its peers as the Iran conflict roils European and Asian markets. For investors who believe the ceasefire holds, I think AVIV is a buy here. Fund Breakdown AVIV was launched by Avantis (part of American Century Investments) with a mandate to achieve broad diversification by investing in a wide set of large-cap companies across non-U.S. developed countries, specifically emphasizing key valuation signals. The fund pursues the same core philosophy Avantis applies across all its offerings—the benefits of indexing (diversification, low turnover, transparency) combined with daily oversight to tilt toward securities with higher expected returns using information in current prices. As noted in the fund's fact sheet , the portfolio management team is led by Eduardo Repetto, Ph.D., with support from Ted Randall, Daniel Ong, CFA, Mitchell Firestein, and Matthew Dubin—they are all veterans from Dimensional Fund Advisors, which gives me reasonable confidence in the pedigree of the process. The expense ratio of 0.25% is solid for an active fund. The closest passive alternative—the iShares MSCI EAFE Value ETF ( EFV ) and iShares MSCI Intl Value Factor ETF ( IVLU )—charges 0.30 % for strictly passive exposure to a...
In this article BIZD PRSD ARES Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 14:39 14:39 Market volatility is pushing investors back to basics in the ETF industry ETF Edge Fears of a private credit crisis are rising as firms at the heart of the growing, but less liquid and less transparent, bond market face investor redemptions . That stress test has arrived just as private loans...
In this article BIZD PRSD ARES Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 14:39 14:39 Market volatility is pushing investors back to basics in the ETF industry ETF Edge Fears of a private credit crisis are rising as firms at the heart of the growing, but less liquid and less transparent, bond market face investor redemptions . That stress test has arrived just as private loans became more prevalent in the ETF market. It was a little over a year ago that the Securities and Exchange Commission approved the first ETF branded as a private credit fund. For ETF investors, the good news it that the risks represented by the asset class are showing up in a more controlled way, as ETFs invest directly in private credit issues are still limited in how much exposure they can have to the asset class — up to, but not exceeding 35%. Some other, older ETF products that are tied to private credit get indirect exposure only, according to Todd Rosenbluth, head of research at VettaFi , said on CNBC's "ETF Edge. They use vehicles like business development companies and closed end funds that primarily invest in the private credit sector. While that adds liquidity compared to holding private loans directly, it is not without investor concern in the current environment. The VanEck BDC Income ETF ( BIZD ), which has roughly $1.5 billion in assets and dates back to 2013, is down 13% since the start of the year. The reason is clear: among BIZD's top holdings are publicly traded shares of some of the private credit managers in the news, including Blue Owl Capital and Ares Capital . Blue Owl shares are down over 46% this year. The Simplify VettaFi Private Credit Strategy ETF ( PCR ) is down around 20% in the past year and also focused its investments in business development companies and closed end funds. Stock Chart Icon Stock chart icon PCR YTD Liquidity remains the main concern for investors, and private credit is not meant for daily trading the way ETFs are, which has r...
Christina Ruffini and Matt Miller take a field trip to the largest attended motor event in the US - the New York Auto Show. Watch the Bloomberg This Weekend LIVE every Saturday and Sunday morning. (Source: Bloomberg)
Christina Ruffini and Matt Miller take a field trip to the largest attended motor event in the US - the New York Auto Show. Watch the Bloomberg This Weekend LIVE every Saturday and Sunday morning. (Source: Bloomberg)
For Arsenal’s longsuffering supporters, the emotional strain is reaching unbearable levels. They could only watch in stunned disbelief as Alex Scott’s goal 16 minutes from time condemned the Premier League leaders to a defeat they must fear will prove to be extremely significant. While Arsenal still lead Manchester City by nine points, a defeat at the Etihad next Sunday could give City an opportun...
For Arsenal’s longsuffering supporters, the emotional strain is reaching unbearable levels. They could only watch in stunned disbelief as Alex Scott’s goal 16 minutes from time condemned the Premier League leaders to a defeat they must fear will prove to be extremely significant. While Arsenal still lead Manchester City by nine points, a defeat at the Etihad next Sunday could give City an opportunity to draw level on points if they beat Chelsea tomorrow and then win their game in hand against Crystal Palace. Having set the pace since the start of October, that is the nightmare scenario Mikel Arteta and his team must now come to terms with. Continue reading...
The S&P 500 is mixed after March inflation came in just below forecasts and uncertainty over a peaceful resolution to the Iran war. Tech stocks, though, were once again doing the heavy lifting. Right in the middle is Nvidia (NASDAQ:NVDA), which just logged its eighth consecutive session of gains through Friday’s close, with the stock ... Nvidia Just Posted Its Longest Winning Streak Since 2023. Is...
The S&P 500 is mixed after March inflation came in just below forecasts and uncertainty over a peaceful resolution to the Iran war. Tech stocks, though, were once again doing the heavy lifting. Right in the middle is Nvidia (NASDAQ:NVDA), which just logged its eighth consecutive session of gains through Friday’s close, with the stock ... Nvidia Just Posted Its Longest Winning Streak Since 2023. Is This Time for Real?
blackCAT/E+ via Getty Images Thesis The FDA has just approved Eli Lilly’s ( LLY ) latest GLP-1 therapy, Foundayo. It’s tipped to come with a number of advantages to compete on, including price, ease of use, and accessibility, as I'll explain. So, not just innovation alone. Foundayo here would reinforce my buy-case thesis in that it meaningfully lowers barriers to entry via oral dosing, simplified ...
blackCAT/E+ via Getty Images Thesis The FDA has just approved Eli Lilly’s ( LLY ) latest GLP-1 therapy, Foundayo. It’s tipped to come with a number of advantages to compete on, including price, ease of use, and accessibility, as I'll explain. So, not just innovation alone. Foundayo here would reinforce my buy-case thesis in that it meaningfully lowers barriers to entry via oral dosing, simplified administration, competitive pricing, and it is now set to scale distribution via Amazon (AMZN) . I think the Amazon factor is going to be a big deal moving forward, and to me, this is how Lilly will widen their addressable market. It's more about moving into a much larger, more convenience-driven population here, which is where the real volume upside is. In my last coverage , I went over Lilly's latest financials and how they came in such contrast to the competition, and now with the latest commercial moves for Foundayo, I think we could see that gap widening. Eli Lilly and Company Foundayo, how it works As you know, Lilly has just announced that their newly approved drug Foundayo/orforglipron is available for sale in the U.S. Now, I see this as a very big shift for the weight loss market for a number of different reasons. Unlike the earlier GLP-1–based treatments, Foundayo is a once-daily oral pill. It was approved by the U.S. FDA on April 1st of this year, for adults with obesity, or those who are overweight with weight-related conditions. As per the directions, it is to be used alongside diet and exercise. It can be taken at any time throughout the day, with or without food or water, but the tablets must be swallowed whole. So as far as therapies go, this couldn’t be easier for the patient. If we look into the specifics, there are a number of available strengths ranging from 0.8 mg up to about 17.2 mg. That’s to allow for gradual dose escalation depending on tolerability and response. That range is simply there as a dose-escalation strategy, which is pretty standard for ...
Citizen Health CEO and Co-founder Farid Vij, and Citizen Health Chief Business Officer and Co-founder Nasha Fitter. Citizen Health A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. When Nasha Fitter's youngest daughter was diagnosed with FOXG1 syndrome in 2017, a rare genetic neurodevelopmental disorder, she faced a challenge that many in the rare disease ...
Citizen Health CEO and Co-founder Farid Vij, and Citizen Health Chief Business Officer and Co-founder Nasha Fitter. Citizen Health A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. When Nasha Fitter's youngest daughter was diagnosed with FOXG1 syndrome in 2017, a rare genetic neurodevelopmental disorder, she faced a challenge that many in the rare disease community know unfortunately too well: little to no public information about the disease or how to navigate it. "There was really nothing being done," Fitter said. "Just getting day-to-day answers to my questions and the issues I was facing was really unsystematic and random … it was basically going to Facebook and hoping someone would answer my question." Fitter was told at that time that there was no treatment for the syndrome, no research that was underway, and no real roadmap for what might come next for her daughter. To tackle that head on, she co-founded the FOXG1 Research Foundation to work towards a cure. But Fitter, a technology entrepreneur, also saw an opportunity to advance how rare disease patients receive care that could also accelerate finding cures. Working with fellow technology entrepreneur Farid Vij, the two launched Citizen Health in 2023, aiming to build what Vij calls an "AI advocate" for the rare disease community. "The single biggest thing that you can have that will benefit you if you are a patient with a rare disease is an advocate in your corner," Vij said. Often, due to the lack of information and resources available around specific rare diseases, that duty falls on a parent or a loved one. "Thousands of families have a reason to not take no for an answer, so they will try to find the next doctor, they will start a foundation, or they'll try to become scientists themselves and build gene therapy programs," he said. "But most people can't afford to do that, or they don't know how to do that, and it's really hard to democratize that." The impact of...
Amazon (NASDAQ:AMZN) and Walmart (NYSE:WMT) reported earnings revealing two companies of nearly identical scale but radically different profit architectures. Amazon closed fiscal 2025 with annual revenue of $716.92 billion, while Walmart finished fiscal 2026 with $713.16 billion. The revenue gap is negligible, but the strategy gap is enormous. AWS Carries Amazon. Omnichannel Carries Walmart. Amazo...
Amazon (NASDAQ:AMZN) and Walmart (NYSE:WMT) reported earnings revealing two companies of nearly identical scale but radically different profit architectures. Amazon closed fiscal 2025 with annual revenue of $716.92 billion, while Walmart finished fiscal 2026 with $713.16 billion. The revenue gap is negligible, but the strategy gap is enormous. AWS Carries Amazon. Omnichannel Carries Walmart. Amazon’s ... Amazon vs. Walmart: The Retail War Just Picked a Winner